Conditional Antibody Agonists for TNFRSF Receptor Clustering
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody molecules targeting TNFRSF receptors require external crosslinking agents for sufficient receptor activation, leading to inefficient activation of immune cells, particularly in cancer therapy.
Innovation Solution
Development of antibody molecules with CDR-based antigen-binding sites in both variable and constant domains that bind to TNFRSF receptors and tumor antigens, enabling conditional activation of immune cells by mimicking trimeric ligand clustering without the need for external crosslinking agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibody molecules targeting TNFRSF receptors are used, then immune cell activation is achieved, but external crosslinking agents are required for sufficient receptor activation
Solution Approach 1:
The patent combines two antigen-binding sites into a single antibody molecule: one site targets the TNFRSF receptor while the other targets a tumor-associated antigen. This merging eliminates the need for external crosslinking agents by enabling the antibody to simultaneously bind both the receptor and the antigen, thereby achieving sufficient receptor activation through its own structure.
Solution Approach 2:
The antibody molecule acts as an intermediary that bridges the TNFRSF receptor and the tumor-associated antigen. By positioning itself between these two targets, the antibody mediates the clustering effect normally achieved by crosslinking agents, thereby activating the receptor without requiring separate crosslinking components.
2Reliability
If external crosslinking agents are used to activate TNFRSF receptors, then receptor clustering is achieved, but immune cell activation becomes inefficient
Solution Approach 1:
The patent merges the functions of receptor binding and antigen binding into a single antibody molecule. This integration allows the antibody to directly induce receptor clustering upon binding the tumor antigen, thereby achieving efficient immune cell activation without the productivity losses associated with multi-step crosslinking processes.
3Reliability
If antibody molecules bind to TNFRSF receptors without tumor antigen specificity, then off-target activation occurs, but conditional activation in tumor microenvironment is reduced
Solution Approach 1:
The patent applies local quality by making the antibody's agonistic activity conditional upon the local presence of tumor-associated antigens. The antibody only activates TNFRSF receptors in locations where both the receptor and the tumor antigen are present, thereby achieving spatially selective activation that minimizes off-target effects while maximizing tumor microenvironment specificity.
Solution Approach 2:
The patent changes the activation parameter from constitutive to conditional by requiring simultaneous binding to both the TNFRSF receptor and the tumor-associated antigen. This dual-binding requirement acts as a molecular switch that activates the antibody's agonistic function only under the specific parameter condition of tumor antigen presence, thereby eliminating off-target activation in normal tissues.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These antibody molecules effectively induce clustering and signaling of TNFRSF receptors when bound to tumor antigens, enhancing immune cell activation specifically in tumor microenvironments, reducing off-target effects and improving tumor growth suppression.
Implementation Method 1
an antibody molecule, which binds to a tumour antigen and a tumour necrosis factor receptor superfamily (TNFRSF) receptor
Implementation Method 2
This clustering results in the activation of the NFkB intracellular signalling pathway
Implementation Method 3
these changes are then transduced via intracellular proteins that interact with the receptors intracellular domains
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The application relates to antibody molecules, which bind to a first and second antigen, the first antigen being a disease antigen, for example a tumour antigen, and the second antigen being a tumour necrosis factor receptor superfamily (TNFRSF) receptor antigen on the surface of an immune cell. The antibody molecules preferably comprise a CDR-based antigen-binding site and an antigen-binding site, which may be located in two or more structural loops of a constant domain of the antibody molecule. The antibody molecules find application, for example, in cancer therapy.